Cargando…

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene

BACKGROUND: Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutations and MET gene amplification occur in 3–5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKIs) targeting MET alterations have shown promising results in these patients. OBJECTIVE: The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Alessa, Bankel, Lorenz, Hiltbrunner, Stefanie, Rechsteiner, Markus, Rüschoff, Jan H., Rushing, Elisabeth Jane, Britschgi, Christian, Curioni-Fontecedro, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684265/ https://www.ncbi.nlm.nih.gov/pubmed/36136211 http://dx.doi.org/10.1007/s11523-022-00918-6

Ejemplares similares

Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

Genomic landscape of pleural and peritoneal mesothelioma tumours
por: Hiltbrunner, Stefanie, et al.
Publicado: (2022)

Targeting ALK in Neuroendocrine Tumors of the Lung
por: Akhoundova, Dilara, et al.
Publicado: (2022)

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
por: Hiltbrunner, Stefanie, et al.
Publicado: (2023)

Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer
por: Britschgi, Christian, et al.
Publicado: (2018)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
por: Britschgi, Christian, et al.
Publicado: (2020)

The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer
por: Akhoundova, D., et al.
Publicado: (2020)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

A new era of oncology through artificial intelligence
por: Curioni-Fontecedro, Alessandra
Publicado: (2017)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Frequent PD-L1 expression in testicular germ cell tumors
por: Fankhauser, C D, et al.
Publicado: (2015)

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
por: Le, Xiuning, et al.
Publicado: (2021)

Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
por: Grundmann, Eva, et al.
Publicado: (2023)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening
por: Wu, Cheng-Guang, et al.
Publicado: (2020)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

True abscopal effect in a patient with metastatic non-small cell lung cancer
por: Vilinovszki, Oliver, et al.
Publicado: (2021)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro
por: Fontecedro, Alessandra Curioni, et al.
Publicado: (2010)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
por: Inno, Alessandro, et al.
Publicado: (2023)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
por: Li, Jian, et al.
Publicado: (2022)

The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview
por: Jöhrens, Korinna, et al.
Publicado: (2021)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
por: Gürbüz, Mustafa, et al.
Publicado: (2022)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
por: Nitta, Naohiro, et al.
Publicado: (2023)

Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms
por: Haberecker, Martina, et al.
Publicado: (2022)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
por: Song, Kyu Young, et al.
Publicado: (2020)

Outcome Analysis of Treatment Modalities for Thoracic Sarcomas
por: Sarvan, Milos, et al.
Publicado: (2023)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t9b6ar63d1t1vau4sqtldpols1